Fukuda Toru, Kohda Masakazu, Kanomata Kazuhiro, Nojima Junya, Nakamura Atsushi, Kamizono Jyunji, Noguchi Yasuo, Iwakiri Kiyofumi, Kondo Takeo, Kurose Junichi, Endo Ken-ichi, Awakura Takeshi, Fukushi Junichi, Nakashima Yasuharu, Chiyonobu Tomohiro, Kawara Akira, Nishida Yoshihiro, Wada Ikuo, Akita Masumi, Komori Tetsuo, Nakayama Konosuke, Nanba Akira, Maruki Yuichi, Yoda Tetsuya, Tomoda Hiroshi, Yu Paul B, Shore Eileen M, Kaplan Frederick S, Miyazono Kohei, Matsuoka Masaru, Ikebuchi Kenji, Ohtake Akira, Oda Hiromi, Jimi Eijiro, Owan Ichiro, Okazaki Yasushi, Katagiri Takenobu
Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan.
J Biol Chem. 2009 Mar 13;284(11):7149-56. doi: 10.1074/jbc.M801681200. Epub 2008 Aug 6.
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by congenital malformation of the great toes and by progressive heterotopic bone formation in muscle tissue. Recently, a mutation involving a single amino acid substitution in a bone morphogenetic protein (BMP) type I receptor, ALK2, was identified in patients with FOP. We report here that the identical mutation, R206H, was observed in 19 Japanese patients with sporadic FOP. This mutant receptor, ALK2(R206H), activates BMP signaling without ligand binding. Moreover, expression of Smad1 and Smad5 was up-regulated in response to muscular injury. ALK2(R206H) with Smad1 or Smad5 induced osteoblastic differentiation that could be inhibited by Smad7 or dorsomorphin. Taken together, these findings suggest that the heterotopic bone formation in FOP may be induced by a constitutively activated BMP receptor signaling through Smad1 or Smad5. Gene transfer of Smad7 or inhibition of type I receptors with dorsomorphin may represent strategies for blocking the activity induced by ALK2(R206H) in FOP.
进行性骨化性纤维发育不良(FOP)是一种罕见的常染色体显性疾病,其特征为大脚趾先天性畸形以及肌肉组织中进行性异位骨形成。最近,在FOP患者中发现了一种涉及骨形态发生蛋白(BMP)I型受体ALK2中单个氨基酸替代的突变。我们在此报告,在19例日本散发性FOP患者中观察到了相同的突变R206H。这种突变受体ALK2(R206H)在没有配体结合的情况下激活BMP信号传导。此外,响应肌肉损伤,Smad1和Smad5的表达上调。带有Smad1或Smad5的ALK2(R206H)诱导成骨细胞分化,而这种分化可被Smad7或多效唑抑制。综上所述,这些发现表明FOP中的异位骨形成可能是由通过Smad1或Smad5的组成型激活的BMP受体信号传导诱导的。Smad7的基因转移或用多效唑抑制I型受体可能代表了阻断ALK2(R206H)在FOP中诱导的活性的策略。
Biochem Biophys Res Commun. 2008-12-19
Curr Drug Targets. 2025
Nat Rev Rheumatol. 2025-2
Radiol Case Rep. 2024-5-3
Biomolecules. 2024-1-24
Biomolecules. 2024-1-12
J Bone Miner Metab. 2008
Circ Res. 2008-4-25
Nat Chem Biol. 2008-1
J Biol Chem. 2007-7-13
J Bone Joint Surg Am. 2007-2
Ann N Y Acad Sci. 2006-4
Biochem Biophys Res Commun. 2006-7-7